Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.42 |
| ▸ | CA12 | O43570 | 5/20 | 0.42 |
| ▸ | MMP2 | P08253 | 5/20 | 0.42 |
| ▸ | CA1 | P00915 | 5/20 | 0.42 |
| ▸ | MMP1 | P03956 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | MMP8 | P22894 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2452794 | 0.87 | CA12 (0.41) | CA2CA12MMP2CA1MMP1 | |
| SCHEMBL8132488 | 0.84 | CA12 (0.42) | CA2CA12MMP2CA1MMP1 | |
| SCHEMBL12011596 | 0.80 | SMN1; SMN2 (0.39) | CA2CA12MMP2CA1MMP1 | |
| SCHEMBL10366299 | 0.80 | MMP1 (0.39) | CA2CA12MMP2CA1MMP1 | |
| SCHEMBL2978531 | 0.77 | SMN1; SMN2 (0.41) | CA2CA12MMP2CA1MMP1 | |
| SCHEMBL2403902 | 0.77 | GABRR1 (0.39) | CA2CA12MMP2CA1MMP1 | |
| Phosphoric Acid SCHEMBL28708565 | 0.76 | CA12 (0.44) | CA2CA12MMP2CA1MMP1 | |
| SCHEMBL2978555 | 0.75 | ALDH1A1 (0.42) | MMP2MMP1MMP3TDP1ALDH1A1 | |
| SCHEMBL12549416 | 0.75 | SMN1; SMN2 (0.44) | CA2CA12MMP2CA1MMP1 | |
| SCHEMBL11957056 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4066690-A | CHEMICAL INTERMEDIATES FOR PROSTAGLANDINS | HOECHST AKTIENGESELLSCHAFT (DT) | 1978-01-03 | — | — | US | claimed |
| US-20240217930-A1 | SARS-COV-2 MPRO INHIBITOR COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-07-04 | — | — | US | disclosed |
| US-20240024338-A1 | CARBIDOPA AND L-DOPA PRODRUGS AND METHODS OF USE | ABBVIE INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-20180208552-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2018-07-26 | — | — | US | disclosed |
| US-20180079762-A1 | Carbidopa and L-Dopa Prodrugs and Methods of use | ABBVIE INC. (US) | 2018-03-22 | — | — | US | disclosed |
| US-20170081363-A1 | PHARMACEUTICALLY RELEVANT AROMATIC-CATIONIC PEPTIDES | STEALTH BIOTHERAPEUTICS CORP (MC) | 2017-03-23 | — | — | US | disclosed |
| US-20160362431-A1 | Carbidopa And L-Dopa Prodrugs And Methods Of Use | ABBVIE INC. | 2016-12-15 | — | — | US | disclosed |
| US-20160340389-A1 | PHARMACEUTICALLY RELEVANT AROMATIC-CATIONIC PEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2016-11-24 | — | — | US | disclosed |
| US-9446059-B2 | Carbidopa and L-dopa prodrugs and methods of use | ABBVIE INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160106765-A1 | Carbidopa and L-Dopa Prodrugs and Methods of Use | ABBVIE INC. | 2016-04-21 | — | — | US | disclosed |
| US-8273895-B2 | NK1 antagonists | OPKO HEALTH, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-20120156557-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-06-21 | — | — | US | disclosed |
| US-20110098468-A1 | NK1 ANTAGONISTS | OPKO HEALTH, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| EP-2237358-A1 | Nonaqueous electrolyte battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2010-10-06 | — | — | EP | disclosed |
| US-20100035147-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2010-02-11 | — | — | US | disclosed |
| EP-2128923-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY | Mitsubishi Chemical Corporation (JP) | 2009-12-02 | — | — | EP | disclosed |
| US-5811575-A | HEATING 2-CHLOROETHYLPHOSPHONIC ACIDS | CLARIANT GMBH (DE) | 1998-09-22 | — | — | US | disclosed |
| EP-0685484-A2 | Process for preparing vinyl phosphonic acids | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-12-06 | — | — | EP | disclosed |
| US-4066690-A | CHEMICAL INTERMEDIATES FOR PROSTAGLANDINS | HOECHST AKTIENGESELLSCHAFT (DT) | 1978-01-03 | — | — | US | disclosed |
| US-3972923-A | FROM AN ACYL HALIDE AND A PHOSPHONIC ACID DERIVATIVE | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340389-A1 | PHARMACEUTICALLY RELEVANT AROMATIC-CATIONIC PEPTIDES | ADM2, VIP, ANPEP | CA2 1788/4885CA12 2165/4885MMP2 2491/4885 |
| US-20240217930-A1 | SARS-COV-2 MPRO INHIBITOR COMPOUNDS | ACE2, SARS1, ACE | CA2 2692/4885CA12 4567/4885MMP2 3084/4885 |
| US-20170081363-A1 | PHARMACEUTICALLY RELEVANT AROMATIC-CATIONIC PEPTIDES | ADM2, VIP, ANPEP | CA2 1504/4885CA12 2336/4885MMP2 2197/4885 |
| US-20110098468-A1 | NK1 ANTAGONISTS | HRH4, CRHR2, HRH2 | CA2 2999/4885CA12 4144/4885MMP2 4781/4885 |
| US-20160362431-A1 | Carbidopa And L-Dopa Prodrugs And Methods Of Use | COMT, SNCA, PARK7 | CA2 1712/4885CA12 1587/4885MMP2 969/4885 |
| US-20160106765-A1 | Carbidopa and L-Dopa Prodrugs and Methods of Use | COMT, SNCA, PARK7 | CA2 1712/4885CA12 1587/4885MMP2 969/4885 |
| US-20180208552-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | FPR1, FPR2, SAAL1 | CA2 4424/4885CA12 4870/4885MMP2 4028/4885 |
| US-20240024338-A1 | CARBIDOPA AND L-DOPA PRODRUGS AND METHODS OF USE | COMT, SNCA, PARK7 | CA2 1712/4885CA12 1587/4885MMP2 969/4885 |
| US-20180079762-A1 | Carbidopa and L-Dopa Prodrugs and Methods of use | COMT, SNCA, PARK7 | CA2 1712/4885CA12 1587/4885MMP2 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.